Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis

American Journal of Pathology

Volumn 176, Issue 2, 2010, Pages 1006-1017

  Dongiovanni, Paola ^a   Fracanzani, Anna Ludovica ^a   Cairo, Gaetano ^a   Megazzini, Chiara Paola ^a   Gatti, Stefano ^b   Rametta, Raffaela ^a   Fargion, Silvia ^a   Valenti, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; CANCER RISK; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN HEPG2; DOWN REGULATION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; HEMOCHROMATOSIS; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IRON DEFICIENCY; IRON DEPLETION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING;

EID: 76149107519     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090249     Document Type: Article

References (80)

1. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, Cariani E, Sangiovanni A, Tommasini M, Rossini A, Bertelli C, Fatta E, Patriarca V, Brescianini S, Stroffolini T: Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis 2005, 35:27-32
2. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687
3. Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, Fargion S: Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 2001, 35:498-503
4. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff PO, Vidaud D, Charnaux N, Couvert P, Ganne-Carrie N, Trinchet JC, Gattegno L, Beaugrand M: Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008, 134:102-110
5. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S: Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001, 33:647-651
6. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW: Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008, 100:996-1002
7. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loreal O, Campion JP, Launois B, Ramee MP, Brissot P, Deugnier Y: Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995, 22:446-450
8. Wu KJ, Polack A, Dalla-Favera R: Coordinated regulation of iron-controlling genes. H-ferritin and IRP2, by c-MYC, Science 1999, 283:676-679
9. Alberghini A, Recalcati S, Tacchini L, Santambrogio P, Campanella A, Cairo G: Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells. J Biol Chem 2005, 280:30120-30128
10. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T, Tselepis C: Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 2008, 14:379-387
11. Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, Iqbal T, Tselepis C: Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006, 55:1449-1460
12. Whitnall M, Howard J, Ponka P, Richardson DR: A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006, 103:14901-14906
13. Yu Y, Kovacevic Z, Richardson DR: Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6:1982-1994
14. Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-171
15. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11:1306-1313
16. Farazi PA, Glickman J, Horner J, Depinho RA: Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006, 66:4766-4773
17. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602
18. Nakae J, Park BC, Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999, 274:15982-15985
19. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13:23-31
20. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848
21. Zhu Q, Wani G, Yao J, Patnaik S, Wang QE, El-Mahdy MA, Praetorius-Ibba M, Wani AA: The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter. Oncogene 2007, 26:4199 -4208
22. Califano A: SPLASH: structural pattern localization analysis by sequential histograms. Bioinformatics 2000, 16:341-357
23. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A: Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005, 24:2461-2473
24. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bernelli-Zazzera A: Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the "free" iron pool. J Biol Chem 1995, 270:700-703
25. Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, Dong H: Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 2003, 285:E718-E728
26. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G: Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001, 97:3707-3712
27. Recalcati S, Alberghini A, Campanella A, Gianelli U, De Camilli E, Conte D, Cairo G: Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. Haematologica 2006, 91:303-310
28. Cairo G, Recalcati S, Montosi G, Castrusini E, Conte D, Pietrangelo A: Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. Blood 1997, 89:2546-2553
29. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S: Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008, 172:738-747
30. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, Fiorelli G, Fargion S: Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 2003, 35:172-178
31. Brooks CL, Gu W: Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 2004, 3:895-89932
32. Monte M, Benetti R, Collavin L, Marchionni L, Del Sal G, Schneider C: hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem 2004, 279:11744-11752
33. Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB, Jr., Willingham MC, Inoue K: Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 2007, 12:381-394
34. Pabla N, Huang S, Mi QS, Daniel R, Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 2008, 283:6572-6583
35. Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F, Meek D: FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett 2009, 583:621-626
36. Liu H, Lu ZG, Miki Y, Yoshida K: Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 2007, 27:8480-8491
37. Brooks CL, Gu W: How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009, 9:123-128
38. Fukuda N, Saitoh M, Kobayashi N, Miyazono K: Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells. Oncogene 2006, 25:3509-3517
39. Lecona E, Barrasa JI, Olmo N, Llorente B, Turnay J, Lizarbe MA: Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. Mol Cell Biol 2008, 28:4665-4674
40. Prahl M, Vilborg A, Palmberg C, Jornvall H, Asker C, Wiman KG: The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA Helicase A via RNA, FEBS Lett 2008, 582:2173-2177
41. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M: HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003, 100:12009-12014
42. Toyama T, Sasaki Y, Horimoto M, Iyoda K, Yakushijin T, Ohkawa K, Takehara T, Kasahara A, Araki T, Hori M, Hayashi N: Ninjurin1 increases p21 expression and induces cellular senescence in human hepatoma cells. J Hepatol 2004, 41:637-643
43. Chu F, Borthakur A, Sun X, Barkinge J, Gudi R, Hawkins S, Prasad KV: The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis. Apoptosis 2004, 9:83-95
44. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR: Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009, 69:1037-1045
45. Szydlowska M, Roszkowska A: Expression patterns of AMP-deaminase isozymes in human hepatocellular carcinoma (HCC). Mol Cell Biochem 2008, 318:1-5
46. Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S: Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 2004, 23:8310-8319
47. Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, Kasuga M: Role of MAPK phosphatase-1 (MKP-1) in adipocyte differentiation. J Biol Chem 2004, 279:39951-39957
48. -/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009, 174:746-761
49. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB: Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drugresistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28:1669-1681
50. Young AR, Chan EY, Hu XW, Kochl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA: Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci 2006, 119:3888-3900
51. Hirata D, Yamabuki T, Miki D, Ito T, Tsuchiya E, Fujita M, Hosokawa M, Chayama K, Nakamura Y, Daigo Y: Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009, 15:256-266
52. Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY, Li L, Luo HZ, Yang L, Zhou B, Gu J: Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol 2007, 13:3878-3882
53. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM: Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 2008, 27:596-603
54. Katoh H, Shibata T, Kokubu A, Ojima H, Kosuge T, Kanai Y, Hirohashi S: Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes Chromosomes Cancer 2006, 45:1050-1057
55. Otto H, Conz C, Maier P, Wolfle T, Suzuki CK, Jeno P, Rucknagel P, Stahl J, Rospert S: The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex. Proc Natl Acad Sci USA 2005, 102:10064-10069
56. Shibata S, Matsuoka Y, Yoneda Y: Nucleocytoplasmic transport of proteins and poly(A)+ RNA in reconstituted Tpr-less nuclei in living mammalian cells. Genes Cells 2002, 7:421-434
57. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G: Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008, 87:1374-1383
58. Park JM, Kohn MJ, Bruinsma MW, Vech C, Intine RV, Fuhrmann S, Grinberg A, Mukherjee I, Love PE, Ko MS, DePamphilis ML, Maraia RJ: The multifunctional RNA-binding protein La is required for mouse development and for the establishment of embryonic stem cells. Mol Cell Biol 2006, 26:1445-1451
59. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T, Nakanuma Y: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008, 88:873-882
60. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C, Liu H, Keyvanfar K, Chen H, Cao LY, Ahn BH, Kumar NG, Rovira II, Xu XL, van Lohuizen M, Motoyama N, Deng CX, Finkel T: Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009, 459:387-392
61. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H: DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006, 5:1202-1207
62. Wu PC, Lau VK, Fang JW, Lai VC, Lai CL, Lau JY: Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver 1999, 19:444-451
63. Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiishi A, Umino M, Kikuchi F, Sakamoto A, Fujioka Y, Kamma H: Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract 2008, 204:799-807
64. Sharma A, Ray R, Rajeswari MR: Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 2008, 26:843-851
65. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP, Tomlinson IP: Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol 2005, 205:29-40
66. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J: c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008, 68:5326-5334
67. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR: Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 2003, 9:2807-2816
68. Hu C, Chen L, Jiang Y, Li Y, Wang S: The effect of fatty acid-CoA ligase 4 on the growth of hepatic cancer cells. Cancer Biol Ther 2008, 7:131-134
69. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, Maggioni M, Fargion S, Fracanzani AL: Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007, 92:1037-1042
70. Chen X: Cyclin G: a regulator of the p53-Mdm2 network. Dev Cell 2002, 2:518-519
71. Michael D, Oren M: The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002, 12:53-59
72. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK: Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007, 26:3473-3481
73. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, Cavazzini F, Campioni D, Fanin R, Cuneo A, Zauli G: Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:4122-4129
74. Bardos JI, Chau NM, Ashcroft M: Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol Cell Biol 2004, 24:2905-2914
75. Chang DL, Qiu W, Ying H, Zhang Y, Chen CY, Xiao ZX: ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene 2007, 26:4627-4634
76. Fargion S, Fracanzani AL, Piperno A, Braga M, D'Alba R, Ronchi G, Fiorelli G: Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994, 20:1426-1431
77. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D: Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992, 15:655-659
78. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006, 66:5104-5110
79. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J: A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005, 280:26776-26787
80. Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM: Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 2008, 283:33911-33918